CD19 and lymphoma: Recently the U.S. FDA approved two types of CD19-targeting CAR T cells, tisagenlecleucel (KymriahTM–Novartis) in leukemia (August 2017) and lymphoma (May 2018) and axicabtagene ciloleucel (YescartaTM–Kite) in lymphoma (October 2017).